Swipe for more

• June 21, 2024

  bioMérieux receives US FDA 510(k) clearance for its AST System VITEK® REVEAL™

  bioMérieux, a world leader in in vitro diagnostics, today announces that its VITEK® REVEAL™ AST System, reporting results directly from positive blood cultures, has received U.S. Food and Drug Administration (FDA) 510(k) clearance.

  Read more
  

• May 28, 2024

  bioMérieux receives FDA 510(k) clearance of VIDAS® TBI (GFAP, UCH-L1), an innovative test to improve the assessment of patients with mild traumatic brain injury

  bioMérieux, a world leader in the field of in vitro diagnostics, announces the U.S. FDA 510(k) clearance of VIDAS® TBI (GFAP, UCH-L1), a serum-based test to support the assessment of patients with mild traumatic brain injury (mTBI), including concussion.

  Read more
  

• May 23, 2024

  Malawi Ministry of Health, bioMérieux, and Pfizer Form Country’s First Multisectoral Collaboration to Help Address Antimicrobial Resistance

  The Malawi Ministry of Health, bioMérieux, and Pfizer today announced a collaboration to advance Malawi’s first multisectoral initiative which aims to build public sector antimicrobial stewardship (AMS) capacity in infection prevention and control, diagnostics, surveillance, and to guide the appropriate use of antibiotics.

  Read more